Pharmaceutical News and Articles

Free COVID-19 Tests Available Now

The free COVID-19 tests promised by the U.S. government are now available. U.S. households will be eligible to order four free COVID-19 tests at COVIDTests.gov,

Childhood Vaccination Coverage Lower for Children Born in 2020, 2021

Children born in 2020 to 2021 had lower coverage with nearly all childhood vaccines recommended by age 24 months than those born in 2018 and 2019, according to

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

U.S. Restarts Free COVID Test Program

Starting today, the U.S. government is offering another round of free COVID tests. U.S. households will be eligible to order 4 free COVID-19 tests at COVIDTests

Anti-CD20 Therapy Shows No Effect on Disability Progression in MS

For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-

Global Prevalence of Congenital Heart Disease at High Altitude ~9 Percent

The global prevalence of congenital heart disease (CHD) at high altitude is 8.97 percent, according to the results of a review presented at the American College

Gum Disease Germs Could Help Trigger Cancer

Bacteria that causes gum disease can also raise a person s risk of head and neck cancers, a new study says. More than a dozen bacterial species have been linked

FDA Approves Bimzelx for Three New Indications

The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with act

U.S. Suicide Rate Increased to 14.2 Per 100,000 in 2022

The age-adjusted suicide rate increased in 2021 and 2022, following a decline from 2018 to 2020, reaching 14.2 per 100,000 standard population in 2022, accordin

FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneou